Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Patient Profile Presentation: A 56-Year-Old Man with Clear Cell RCC

June 16th 2022

Robert Alter, MD, presents the patient profile of a 56-year-old man with clear cell renal cell carcinoma presenting with hip and leg pain.

Lee Lays Out Treatment Developments in Non–Clear Cell RCC

June 16th 2022

Dr Lee highlights treatment developments in non–clear cell renal cell carcinoma, emphasizes the need for precise classification of the histologic subsets of this disease, and discusses the investigation of cabozantinib plus nivolumab across stratified cohorts of non–clear cell renal cell carcinoma.

Advanced RCC Patient Referrals from Community Oncologists

June 16th 2022

Elan Diamond, MD, describes when and how often community oncologists refer patients with suspected advanced renal cell carcinoma to his practice.

Immunotherapy Combinations Contribute to Efficacy and Safety Advances in Genitourinary Cancer Treatment

June 16th 2022

New treatment strategies with immunotherapeutic agents are challenging standards of care and prolonging survival in first and later lines of metastatic urothelial carcinoma, metastatic renal cell carcinoma, and metastatic castration-resistant prostate cancer.

Toolbox Overflows With First-Line Combination Regimens for Advanced RCC

June 14th 2022

Mehmet A. Bilen, MD, and a panel of renal cell carcinoma experts discuss the preferred treatment options for patients with intermediate-risk or high-risk advanced renal cell carcinoma and the clinical features that may influence their decisions.

Nivolumab + Ipilimumab Combination Regimen for Advanced RCC

June 8th 2022

Oncologists review the IO/IO combination regimens available for treatment of advanced RCC and discuss patient selection for treatment with nivolumab and ipilimumab.

Patient Profile Presentation: A 70-Year-Old Man with Stage 4 Clear Cell RCC

June 8th 2022

Dr Elan Diamond presents the patient profile of a 70-year-old man with stage IV clear cell renal cell carcinoma.

Latest in Lung, Genitourinary, Gynecologic, and Breast Cancers From ASCO 2022: Drs Charu Aggarwal, Bradley McGregor, Robert Coleman, and Kevin Kalinsky

June 7th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Lenvatinib Plus Pembrolizumab Improves PFS2 Outcomes in Advanced RCC

June 5th 2022

Patients with advanced renal cell carcinoma who received lenvatinib plus pembrolizumab experienced a longer time to progression on next line of therapy compared with those who received sunitinib.

Adjuvant Everolimus Displays RFS Benefit in Very High-Risk RCC

June 4th 2022

Adjuvant everolimus significantly improved recurrence-free survival when compared with placebo in patients with very high-risk renal cell carcinoma.

Sequencing Therapies for Advanced RCC

June 2nd 2022

Experts discuss how they sequence I/O–TKI treatments for advanced renal cell carcinoma.

Toxicities with IO-TKI Combination Regimens for Advanced RCC and Their Management

June 2nd 2022

Elan Diamond, MD, explains toxicities commonly seen with I/O–TKI combination regimens, how to manage them, and how to discuss toxicities with patients with advanced renal cell carcinoma.

OncLive Honors 13 Cancer Care Pioneers

June 2nd 2022

For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Heightened Histological Focus Fosters Treatment Advances in Non-clear Cell RCC

June 1st 2022

Chung-Han Lee, MD, PhD, explains the historical barriers to treatment developments in non-clear cell renal cell carcinoma; highlights the efficacy of cabozantinib plus nivolumab in patients with unclassified, translocation, papillary, and fumarate hydratase–deficient non-clear cell renal cell carcinoma; and elaborates on the need for increased molecular classification of the histologic subsets of non-clear cell renal cell carcinoma.

Dr. Vaishampayan on the Rationale of the PROBE Trial in RCC

June 1st 2022

Ulka Nitin Vaishampayan, MBBS, discusses the rationale of the phase 3 PROBE trial in advanced renal cell carcinoma.

Dr. Daneshmand on Emerging Treatments in Bladder Cancer

May 26th 2022

Sia Daneshmand MD, discusses emerging treatments in bladder cancer.

Front-Line Lenvatinib + Pembrolizumab Combination Regimens for Advanced RCC: Selecting Patients and Dose

May 25th 2022

A review of the first-line I/O-TKI combination regimens available for advanced RCC and selecting the right patients and dose for treatment with lenvatinib and pembrolizumab.

Patient Profile Presentation: A 56-Year-Old Man with Metastatic Clear Cell RCC

May 25th 2022

Robert Alter, MD, presents the patient profile of a 56-year-old man with metastatic clear cell renal cell carcinoma presenting with chromaturia.

Nivolumab Plus Axitinib Generates Promising Responses in Untreated Advanced RCC

May 24th 2022

The combination of nivolumab and axitinib achieved meaningful responses in treatment-naïve advanced renal cell carcinoma, according to results from a phase 1/2 trial (NCT03172754) presented at the 2022 Genitourinary Cancers Symposium.

Kevin Hakimi on the Rationale of the PADRES Trial in RCC

May 24th 2022

Kevin Hakimi, discusses the rationale for the phase 2 PADRES trial in clear cell renal cell carcinoma.